Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 9/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8668033 | 0.96 | CCR3 (0.41) | CCR3MCHR1NPSR1SLC6A12TMEM97 | |
| SCHEMBL8504375 | 0.93 | CCR3 (0.38) | CCR3MCHR1NPSR1SLC6A12TMEM97 | |
| SCHEMBL8485533 | 0.88 | NPSR1 (0.42) | CCR3MCHR1NPSR1SLC6A12TMEM97 | |
| SCHEMBL8482320 | 0.88 | NPY5R (0.37) | — | |
| SCHEMBL8484454 | 0.86 | NPSR1 (0.42) | CCR3MCHR1NPSR1SLC6A12TMEM97 | |
| SCHEMBL8666005 | 0.84 | NPY5R (0.36) | — | |
| SCHEMBL8665880 | 0.84 | UTS2R (0.39) | MCHR1NPSR1 | |
| SCHEMBL8648475 | 0.83 | CCR3 (0.39) | CCR3MCHR1HTR7CCNE1CDK2 | |
| SCHEMBL8479703 | 0.83 | CCR3 (0.42) | CCR3MCHR1NPSR1SLC6A12TMEM97 | |
| SCHEMBL8483684 | 0.81 | NPSR1 (0.41) | CCR3MCHR1NPSR1SLC6A12TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |